| Breast cancer guidelines | NICE guideline | TBC |
| Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma [ID6334] | Technology appraisal guidance | |
| Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325] | Technology appraisal guidance | |
| Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ] | Technology appraisal guidance | TBC |
| Cabotegravir for preventing HIV-1 in adults and young people [ID6255] | Technology appraisal guidance | |
| Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243] | Technology appraisal guidance | |
| Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment ID6474 | Technology appraisal guidance | |
| Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330] | Technology appraisal guidance | TBC |
| Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653] | Technology appraisal guidance | TBC |
| Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370] | Technology appraisal guidance | |